Bugula neritina

Bugula neritina (commonly known as brown bryozoan or common bugula) is a cryptic species complex of sessile marine animal in the genus Bugula.[2]

Bugula neritina
The nudibranch Diaphorodoris papillata feeding on Bugula neritina
Scientific classification edit
Kingdom: Animalia
Phylum: Bryozoa
Class: Gymnolaemata
Order: Cheilostomatida
Family: Bugulidae
Genus: Bugula
Species:
B. neritina
Binomial name
Bugula neritina
Synonyms[2]

Sertularia neritina Linnaeus, 1758 (basionym)

It is invasive with a cosmopolitan distribution.[1]

Bugula neritina is of interest from a drug discovery perspective because its bacterial symbiont, Candidatus Endobugula sertula,[3] produces the bryostatins, a group of around twenty bioactive natural products. The bryostatins are under investigation for their therapeutic potential directed at cancer immunotherapy,[4][5] treatment of Alzheimer's disease,[5][6] and HIV/AIDS eradication,[7] due to their low toxicity and antineoplastic activity.[8]

The draft whole genome of Bugula neritina has recently been sequenced.[9] This adds to the growing number of genomes on the total list of sequenced animal genomes.

Bugula neritina is also of interest in materials science, where it is used as a model organism in biofouling studies.[10]

References
  1. "Bugula neritina (brown bryozoan)". CABI (organisation). 3 May 2013. Retrieved 14 March 2015.
  2. Gordon, D. (2015). Bugula neritina (Linnaeus, 1758). In: Bock, P.; Gordon, D. (2015) World List of Bryozoa. Accessed through: World Register of Marine Species at http://www.marinespecies.org/aphia.php?p=taxdetails&id=111158 on 2015-09-02
  3. Li, Hai; Mishra, Mrinal; Ding, Shaoxiong; Miyamoto, Michael M. (2018-08-23). "Diversity and Dynamics of "Candidatus Endobugula" and Other Symbiotic Bacteria in Chinese Populations of the Bryozoan, Bugula neritina". Microbial Ecology. 77 (1): 243–256. doi:10.1007/s00248-018-1233-x. ISSN 0095-3628. PMID 30141128. S2CID 52077233.
  4. Singh R, Sharma M, Joshi P, Rawat DS (2008). "Clinical status of anti-cancer agents derived from marine sources". Anticancer Agents Med Chem. 8 (6): 603–617. doi:10.2174/187152008785133074. PMID 18690825.
  5. Ruan BF, Zhu HL (2012). "The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development". Curr Med Chem. 19 (16): 2652–64. doi:10.2174/092986712800493020. PMID 22506770.
  6. "Bryostatin – Phase II clinical testing of a non-toxic PKC activator". Blanchette Rockefeller Neurosciences Institute (West Virginia University). Retrieved 14 March 2015.
  7. Wender, P. A.; Kee, J.-M.; Warrington, J. M. (2008-05-02). "Practical Synthesis of Prostratin, DPP, and Their Analogs, Adjuvant Leads Against Latent HIV". Science. 320 (5876): 649–652. Bibcode:2008Sci...320..649W. doi:10.1126/science.1154690. ISSN 0036-8075. PMC 2704988. PMID 18451298.
  8. Figuerola, Blanca; Avila, Conxita (2019-06-04). "The Understudied Phylum Bryozoa as a Promising Source of Anticancer Drugs". doi:10.20944/preprints201906.0029.v1. S2CID 195387997. {{cite journal}}: Cite journal requires |journal= (help)
  9. Rayko M, Komissarov A, Lim-Fong G, Rhodes AC, Kwan JC, Kliver S, Chesnokova P, O'Brien SJ, Lopez JV (September 2020). "Draft genome of Bryozoan Bugula neritina – a colonial animal packing powerful symbionts and potential medicines". Scientific Data. 7 (1): 356. doi:10.1038/s41597-020-00684-y. PMC 7576161. PMID 33082320.
  10. Yua X, Yana Y, Gua JD (2007). "Attachment of the biofouling bryozoan Bugula neritina larvae affected by inorganic and organic chemical cues". Int Biodeterior Biodegradation. 60 (2): 81–89. doi:10.1016/j.ibiod.2006.12.003.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.